1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Procter & Gamble Health Limited

Procter & Gamble Health Limited

PGHL.BO
Procter & Gamble Health LimitedIN flagBombay Stock Exchange
6,831.95
INR
+209.95
- -
113.23BMarket Cap
Procter & Gamble Health Limited
PGHL.BO
(Bombay Stock Exchange)

Recent

price

6,831.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2026
TTM
FRC
282.1
306.69
333.52
413.05
478.31
519.84
564.82
597.95
420.58
492.9
558.21
596.88
657.88
726.45
680.44
848.2
848.99
Revenue per Share
39.04
38.06
38.36
47.23
33.66
26.04
32.27
47.67
56.57
505.27
95.64
106.51
115.98
138.24
121.08
196.94
197.12
Basic EPS, GAAP
19.19
34.45
2.25
24.49
-19.86
-21.34
23.06
45.42
14.07
-94.65
91.12
117.28
79.28
116.58
124.44
194.15
- -
Free Cash Flow per Basic Share
17.57
114.43
- -
- -
2.5
8.57
5.98
7.5
11
15.04
439.31
230
171
56.5
250
204.99
- -
Dividend per Share
9.9
10
50.55
90.15
110.5
126.74
152.44
185.72
227.55
713.62
10
207.42
152.82
233.45
104.93
10
10.01
Book Value per Share
278.63
208.69
246.9
291.29
314.93
333.81
361.97
399.8
441.26
927.55
491.87
423.87
371.37
451.79
323.67
315.72
316.02
Tangible Book Value per Share
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
Basic Weighted Avg Shares
4,731
5,091
5,536
6,856
7,940
8,629
9,376
9,926
6,981
8,182
9,266
9,908
10,920
12,059
11,295
14,080
14,080
Sales/Revenue/Turnover
20.39
18.81
16.12
14.17
8.57
5.4
10.59
13.3
18.52
15.62
20.12
22.72
22.69
24.53
24.71
30.76
30.76
Operating Margin (%)
75
71
80
89
101
127
234
248
264
250
172
300
271
281
274
236
236
Depreciation Expense
655
632
637
784
559
432
536
791
939
8,387
1,588
1,768
1,925
2,295
2,010
3,269
3,269
Net Income, GAAP
32.11
33.99
33.38
32.87
36.68
35.07
35.73
31.3
38.27
35.6
32.26
24.21
24.02
26.97
26.47
27.33
27.33
Effective Tax Rate (%)
13.84
12.41
11.5
11.43
7.04
5.01
5.71
7.97
13.45
102.51
17.13
17.84
17.63
19.03
17.79
23.22
23.22
Profit Margin (%)
3,816
2,715
3,029
3,614
3,658
3,634
4,140
4,497
5,271
13,415
6,229
4,882
3,761
4,922
3,053
3,013
3,013
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
29
- -
89
69
57
57
LT Debt
4,673
3,464
4,101
4,837
5,230
5,543
6,010
6,638
7,333
15,401
8,168
7,037
6,165
7,509
5,382
5,246
5,246
Total Equity
14.26
15.54
15.75
14.6
8.49
5.55
11.02
14.3
11.2
7.03
10.39
21.76
27.81
30.74
30.89
57.32
57.71
Return on Invested Capital (%)
391.51
380.88
126.74
67.13
33.55
21.95
22.98
27.63
26.78
106.47
26.29
96.28
63.39
70.13
69.1
312.29
1,306.36
Return on Capital (%)
391.39
380.6
126.71
67.13
33.55
21.95
23.12
28.19
27.38
107.37
26.43
97.98
64.39
71.58
71.56
342.73
1,969.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
28
- -
36
LT Borrowings
- -
- -
- -
LT Finance Leases
34
- -
57
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
- -
17
Market Capitalization
104,659
94,545
79,572

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
6,393
- -
5,563
Cash, Cash Equivalents & STI
3,021
- -
2,015
Accounts Receivable, Net
1,375
- -
1,643
Inventories
1,273
- -
1,366
Total Current Liabilities
2,225
- -
2,549
Payables & Accruals
- -
- -
- -
ST Debt
28
- -
36
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
-7.06%
-2.54%
Free Cash Flow
-104.28%
21.23%
56.02%
Net Income, GAAP
89.21%
17.94%
62.66%
Sales/Revenue/Turnover
6.12%
9.18%
24.66%
Total Cash Common Dividend
308.33%
36.84%
-18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,049
3,100
2,525
2,621
11,295
2026
3,249
3,739
3,704
3,387
14,080

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39.5
43.42
28
- -
121.08
2026
53.54
46.74
56.99
39.87
196.94

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
250
2026
- -
- -
- -
- -
204.99
Similar Companies
Can B Corp. (CANB)
Mallinckrodt plc (MNKPF)
Sumitomo Pharma Co., Ltd. (4506.T)
Silo Wellness Inc. (SILFF)
Bal Pharma Limited (BALPHARMA.BO)
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS)
Business
Procter & Gamble Health Limited manufactures and markets over-the-counter healthcare products, vitamins, minerals, and dietary supplements in India and internationally; core offerings include renowned brands such as Neurobion for nerve health, Vicks for cold and cough relief, Evion for vitamin E supplementation, Nasivion nasal decongestants, Polybion B-complex vitamins, Livogen iron supplements, Cosome for skin care, and Seven Seas cod liver oil products. The company, founded in 1967 as a Merck subsidiary and listed publicly in 1981, maintains headquarters in Mumbai, Maharashtra, with primary manufacturing at a GMP-certified facility in Usgaon, Goa, that produces ampoules, softgel capsules, and exports to 13 countries; Procter & Gamble Overseas India B.V. holds a 51.81% stake. In December 2018, Procter & Gamble acquired Merck's Consumer Health business, rebranding the entity as Procter & Gamble Health Limited and focusing operations on vitamins, minerals, and supplements; recent initiatives encompass partnerships with the Indian Academy of Pediatrics for school-based healthcare programs, HelpAge India for mobile health units, the Indian Medical Association for neurology awareness conclaves, and pharmacy waste management collaborations, alongside a September 2025 adjustment to product maximum retail prices following India's GST rate changes and shareholder approval in November 2025 for a new executive director appointment.